Sanofi (NASDAQ:SNY) Stake Lifted by Old Port Advisors

Old Port Advisors lifted its stake in shares of Sanofi (NASDAQ:SNY) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,704 shares of the company’s stock after acquiring an additional 232 shares during the quarter. Old Port Advisors’ holdings in Sanofi were worth $1,770,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the last quarter. Franklin Resources Inc. lifted its stake in Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after buying an additional 246,224 shares in the last quarter. Federated Hermes Inc. grew its position in Sanofi by 26.5% in the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after buying an additional 673,172 shares during the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of Sanofi by 4.1% in the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after buying an additional 114,133 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Up 0.6 %

SNY traded up $0.29 during midday trading on Thursday, hitting $48.52. 357,039 shares of the company’s stock traded hands, compared to its average volume of 2,089,566. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $123.14 billion, a PE ratio of 24.76, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. The stock’s fifty day simple moving average is $49.33 and its 200-day simple moving average is $52.03. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.55 earnings per share. As a group, equities analysts anticipate that Sanofi will post 4.06 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.